TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7749822

Group type: COMPARATOR
Intervention: 0 eggs added per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1 egg added per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 3 eggs added per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake
Number of subjects: 13
Study: 2406105

Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy using the patient's tumor cells to create a vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved surgical techniques and instrumentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further basic scientific and clinical research
Number of subjects: 0
Study: 7413719

Group type: EXPERIMENTAL
Intervention: 3 mg/kg daily of cannabidiol (CBD) for 30 days in healthy volunteers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 200-300 mg daily of cannabidiol (CBD) for 4 1/2 months in epilepsy patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (glucose capsules) for 30 days in healthy volunteers
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 4 1/2 months in epilepsy patients
Number of subjects: 31
Study: 31693265

Group type: EXPERIMENTAL
Intervention: My Guide smartphone application
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: My Health smartphone application
Number of subjects: 80
Study: 29860242

Group type: EXPERIMENTAL
Intervention: Energy-reduced diets varying in macronutrient intake
Number of subjects: 504

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 504
Study: 27886657

Group type: EXPERIMENTAL
Intervention: 10-15-minute brief negotiated interview (BNI)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: 30-45-minute adaptation of motivational interviewing (MOTIV)
Number of subjects: 528

Group type: COMPARATOR
Intervention: No brief intervention (Control)
Number of subjects: 528
Study: 25966826

Group type: EXPERIMENTAL
Intervention: Mean systolic BP in patients who did not experience MACE
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Mean systolic BP before MACE in those who experienced MACE
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Highest quartile based on mean systolic BP
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability of systolic BP
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Inadequate BP control
Number of subjects: 2049
Study: 24028755

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of salbutamol (15 μg/kg IBW/hour)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 326
Study: 21327795

Group type: EXPERIMENTAL
Intervention: Dry immersion for 7 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recovery after dry immersion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standing position after immersion
Number of subjects: 8
Study: 19660492

Group type: EXPERIMENTAL
Intervention: Extended-release morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocodone plus acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18261269

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate and bacillus licheniformis (Group A)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (Group B)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bacillus licheniformis (Group C)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Group A and B vs Group C
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Adverse drug reactions in Group A and B
Number of subjects: 129
Study: 15089956

Group type: EXPERIMENTAL
Intervention: Implementation of an oral analgesic algorithm derived from systematic reviews
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control wards (no intervention initially)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Both intervention and control wards
Number of subjects: 4
Study: 11791961

Group type: EXPERIMENTAL
Intervention: Wheat germ (WG) 2 g, 3 times a day for 10 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg 3 times a day) plus WG
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (cornstarch, 2 g, 3 times a day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metronidazole (250 mg 3 times a day) plus placebo
Number of subjects: 63
Study: 9569649

Group type: EXPERIMENTAL
Intervention: Priming the stereotype of professors or the trait intelligent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming the stereotype of soccer hooligans or the trait stupid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming effects
Number of subjects: 0
Study: 8072199

Group type: EXPERIMENTAL
Intervention: CSF 39-300 (10 micrograms/kg daily via intravenous infusion for 21 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CSF 39-300
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: CSF 39-300 and Placebo
Number of subjects: 53
Study: 3053041

Group type: EXPERIMENTAL
Intervention: Antiplatelet regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28929861

Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (10 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28281111

Group type: EXPERIMENTAL
Intervention: Touch Surgery™ (TS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Virtual Reality (VR) trainer
Number of subjects: 105
Study: 26653668

Group type: EXPERIMENTAL
Intervention: Abatacept (ABT)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (RA control)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ABT/MTX group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ABT
Number of subjects: 111
Study: 24923077

Group type: EXPERIMENTAL
Intervention: 7.5 mg bevacizumab
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 59

Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 59
Study: 21919691

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18640473

Group type: EXPERIMENTAL
Intervention: Metformin 1.5 g/d (MET group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (antioxidants)
Number of subjects: 57
Study: 16570434

Group type: EXPERIMENTAL
Intervention: Jingjin group (acupuncture)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 12844280

Group type: EXPERIMENTAL
Intervention: Combination treatment (benzodiazepines and conventional antipsychotics)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (ziprasidone, risperidone, olanzapine)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 11

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 11
Study: 10475514

Group type: EXPERIMENTAL
Intervention: 0.0625% sodium lauryl sulfate (SLS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 0.125% sodium lauryl sulfate (SLS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 0.25% sodium lauryl sulfate (SLS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 0.5% sodium lauryl sulfate (SLS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 1.0% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study: 7847265

Group type: EXPERIMENTAL
Intervention: CT + TS
Number of subjects: 150

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 150
Study: 2017017

Group type: EXPERIMENTAL
Intervention: Low carbohydrate (LCHO) diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Moderate carbohydrate (MCHO) diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: High carbohydrate (HCHO) diet
Number of subjects: 7
Study: 7137533

Group type: EXPERIMENTAL
Intervention: Partially purified timothy extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two timothy major allergens (Nos. 19 and 25)
Number of subjects: 0
Study: 30958358

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Higher DST variability
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Gait speed in ApoE4 carriers
Number of subjects: 410
Study: 28061907

Group type: EXPERIMENTAL
Intervention: GFF MDI 72/9.6 μg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GFF MDI 36/9.6 μg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monocomponent MDIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium DPI 18 μg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: FF DPI 12 μg BID
Number of subjects: 0
Study: 23901048

Group type: EXPERIMENTAL
Intervention: Informed decision-making (IDM) scores based on patient responses to 10 questions about decision-making.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Age at the time of decision-making
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Years of education
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Presence of a warning about progressing to end-stage kidney disease
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Communication about risks and burdens of dialysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Option of not starting dialysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Perception of choice about starting dialysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Feeling rushed to make a decision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Perception of decision-making by the doctor
Number of subjects: 99
Study: 21437522

Group type: EXPERIMENTAL
Intervention: Topical combination of benzoyl peroxide 5% and clindamycin 1%
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo gel cream
Number of subjects: 23
Study: 19884606

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy (CBASP) and continued pharmacotherapy (MEDS)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP) and continued pharmacotherapy (MEDS)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Continued optimized pharmacotherapy (MEDS) alone
Number of subjects: 491
Study: 17301637

Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels
Number of subjects: 7388

Group type: EXPERIMENTAL
Intervention: Smoking (25 g/day or more)
Number of subjects: 7388

Group type: EXPERIMENTAL
Intervention: Elevated blood pressure
Number of subjects: 7388

Group type: EXPERIMENTAL
Intervention: Increase in serum cholesterol of 1 mmol/l
Number of subjects: 7388
Study: 15073097

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 6415

Group type: EXPERIMENTAL
Intervention: PSA screening with > or = 4 microg/liter
Number of subjects: 6415

Group type: EXPERIMENTAL
Intervention: Overall detection of clinically localized cancers
Number of subjects: 6415
Study: 11141144

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily for one week, then 20 mg once daily for 11 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11092283

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Standard care plus metformin
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Standard care plus placebo
Number of subjects: 3234
Study: 9321764

Group type: EXPERIMENTAL
Intervention: Simplified PCR based assay for NAT2 genotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid as probe drug
Number of subjects: 0
Study: 8462143

Group type: EXPERIMENTAL
Intervention: 0.6 mg sublingual GTN
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 25
Study: 2947102

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29370143

Group type: EXPERIMENTAL
Intervention: CHO-REPLACE (15% carbohydrate solution; 221.4 ± 59.3 g maltodextrin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHO-DEFICIT (non-caloric artificially-sweetened placebo solution)
Number of subjects: 14
Study: 27801937

Group type: EXPERIMENTAL
Intervention: Self-reported sleep apnea (when APOE ɛ4 allele is absent)
Number of subjects: 7547

Group type: EXPERIMENTAL
Intervention: Self-reported sleep apnea (when APOE ɛ4 allele is present)
Number of subjects: 7547
Study: 25108305

Group type: EXPERIMENTAL
Intervention: HRP2-based rapid diagnostic test (RDT)
Number of subjects: 0
Study: 23254579

Group type: EXPERIMENTAL
Intervention: Losartan/hydrochlorothiazide (n = 26)
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-dose ARB (n = 22)
Number of subjects: 48
Study: 20403303

Group type: EXPERIMENTAL
Intervention: Dyract Seal (DS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fissurit F (FF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fissurit FX (FFX)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Admira Seal (AS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All sealants
Number of subjects: 80
Study: 18346603

Group type: EXPERIMENTAL
Intervention: Silence (blocking noise)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Noise (ambient operating room noise)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Music (patient-selected music)
Number of subjects: 63
Study: 15845509

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 vaccine (10^9 CFU buffered with 1.3% NaHCO3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (buffer alone)
Number of subjects: 45
Study: 12218274

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (940 ppm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 13
Study: 10355070

Group type: EXPERIMENTAL
Intervention: Sotalol (2 x 160 mg)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (3 x 160 mg + 3 x 80 mg)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Sotalol, Quinidine + Verapamil, Placebo
Number of subjects: 900
Study: 9064391

Group type: EXPERIMENTAL
Intervention: anti-CEA MoAb 99mTc‐BW 431/26
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: anti-TAG-72 MoAb 111In‐CYT‐103
Number of subjects: 143
Study: 1663244

Group type: EXPERIMENTAL
Intervention: Individualized educational program provided by nurses to modify maternal attitudes towards feeding.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study: 29343175

Group type: EXPERIMENTAL
Intervention: Client-centered care model
Number of subjects: 13
Study: 27719689

Group type: EXPERIMENTAL
Intervention: KICk‐OFF education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23242378

Group type: EXPERIMENTAL
Intervention: Preserving-remnant group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Removing-remnant group
Number of subjects: 62
Study: 22513778

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1492
Study: 20022206

Group type: EXPERIMENTAL
Intervention: Perioperative β-blockers
Number of subjects: 0
Study: 18971181

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of nalmefene (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple intravenous doses of nalmefene (2 mg once daily for 6 days)
Number of subjects: 12
Study: 16827629

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 12801736

Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (50 g every 6 hours for 3 days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 11192146

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 to 12 mg/d
Number of subjects: 1475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1475
Study: 9238896

Group type: EXPERIMENTAL
Intervention: Crest Tartar Control dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest Regular non-tartar control dentifrice
Number of subjects: 0
Study: 1484579

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 525

Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 525
Study: 2862297

Group type: EXPERIMENTAL
Intervention: Oral triazolam 0.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29717362

Group type: EXPERIMENTAL
Intervention: Nylon sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coated polyglactin sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyester sutures
Number of subjects: 0
Study: 29527973

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (barbers encouraged meetings with specialty-trained pharmacists who prescribed drug therapy)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Active control (barbers encouraged lifestyle modification and doctor appointments)
Number of subjects: 319
Study: 27114512

Group type: EXPERIMENTAL
Intervention: Music intervention (12 sessions targeting temporal structure learning using triple meter in music)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Play control (12 sessions of multimodal, social, repetitive play without music)
Number of subjects: 2
Study: 25214778

Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21605879

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: HF unit
Number of subjects: 208
Study: 21070705

Group type: EXPERIMENTAL
Intervention: Diluted formocresol (DFC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 152
Study: 17478265

Group type: EXPERIMENTAL
Intervention: Community-based interventions (5 to 12 sessions) and school interventions (11 to 15 sessions) for 6th and 7th graders
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Community-based interventions
Number of subjects: 28
Study: 16275807

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: D-serine (2 g/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 12175391

Group type: EXPERIMENTAL
Intervention: Prosthetic graft replacement (circular reinforced PTFE and Dacron silver grafts) after resection of inferior vena cava (IVC) and iliofemoral vein.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prosthetic graft replacement after aggressive venous surgery for complete tumor resection.
Number of subjects: 7
Study: 9458208

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 141
Study: 7869442

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1695304

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg b.i.d.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg b.i.d.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg b.i.d.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 366145

Group type: EXPERIMENTAL
Intervention: Levamisole treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro levamisole added to lymphocyte culture prior to drug treatment
Number of subjects: 0
Study: 31680493

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus magnesium sulfate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus hydrocortisone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate plus hydrocortisone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 120
Study: 31479863

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28716815

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks + paclitaxel
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo + paclitaxel
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study: 25736164

Group type: EXPERIMENTAL
Intervention: Siltuximab 11 mg/kg every 3 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 23751377

Group type: EXPERIMENTAL
Intervention: Pre-randomization 3D real time review (RTR)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Post-randomization 2D real time review (RTR)
Number of subjects: 340
Study: 21272712

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy plus physical therapy (MET plus PT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 76
Study: 19794165

Group type: EXPERIMENTAL
Intervention: Double bundle anterior cruciate ligament reconstruction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single bundle using Endobutton for femoral fixation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single bundle using RigidFix cross pins for femoral fixation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single bundle using bioabsorbable TransFix II screw for femoral fixation
Number of subjects: 200